Flaxseed supplementation in hyperlipidemic patients

January 1, 2005 Human Health and Nutrition Data 0 Comments

Flaxseed supplementation in hyperlipidemic patients

Year: 2005
Authors: Mandaşescu, S., Mocanu, V., Dăscaliţa, A.M., Haliga, R., Nestian, I., Stitt, P.A., Luca, V.
Publication Name: Rev. Med. Chir. Soc. Med. Nat. Iasi.
Publication Details: Volume 109; Number 3; Pages 502-6.


The aim of this study was to investigate the effect of daily consumption of dietary flaxseed (as a source of linolenic acid, LNA) on plasma lipid concentrations in mildly hyperlipidemic patients. METHODS: 40 hyperlipidemic patients with plasma total cholesterol greater than 240 mg/dL were distributed in 3 groups: 10 patients who received hypo-lipidic diet (diet group), 10 patients who received hypo-lipidic diet plus statins (diet+HL group), 20 patients who received hypo-lipidic diet plus 20 g ground flax-seeds/day (diet+flax group). Body mass index (BMI), serum total cholesterol (TC), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), triglycerides (TG) and cholesterol/HDL-cholesterol ratio were measured at the beginning and after 60 days of treatment. RESULTS: Flaxseed supplementation was associated with significant reductions in TC (-17.2%), LDL-C (-3.9%), TG (-36.3%) and TC/HDL-C ratio (-33.5%). There were no significant differences in absolute change in BMI nor in percentage change in TC, HDL-C, LDL-C, TC/HDL-C ratio between flaxseed and statin groups. CONCLUSIONS: Dietary flaxseed significantly improves lipid profile in hyperlipidemic patients and may favorably modify cardiovascular risk factors. Author's Abstract.

Back to Databases

Affiliated Organizations

Flax Focus Newsletter

Stay up-to-date with important flax news and announcements with our FLAX FOCUS newsletter.